ArticleBJC reports2026
High expression of the ADC target Claudin-6 associates with aggressive endometrial cancer and remains high in metastatic lesions.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients with advanced or recurrent endometrial cancer (EC) have limited treatment options. The development of antibody-drug conjugates (ADCs) offers new treatment strategies by targeted delivery of cytotoxic payloads, including conventional chemotherapy, to cancer cells. An ADC targeting Claudin-6 is currently in clinical testing however expression patterns of Claudin-6 has not been thoroughly explored in EC.
methodsMembrane expression of Claudin-6 was evaluated by immunohistochemistry in a large, prospectively collected EC cohort with 1106 primary tumours and 187 metastatic lesions. Claudin-6 expression was scored according to the Gastric criteria and correlated with clinicopathological characteristics and follow-up data.
resultsClaudin-6 expression was detected in 18% of ECs and was highly expressed in 10% of all samples. High expression was observed in 49% of serous tumours and 22% of carcinosarcomas. High Claudin-6 independently predicted poor disease-specific survival in multivariate analysis (HR: 1.7, CI: 1.2-2.4, p = 0.002). In the paired primary-metastasis cohort, Claudin-6 was highly expressed in 19% of primary tumours and, of these, 77% maintained high expression in at least one corresponding metastatic lesion.
conclusionsOur study identified Claudin-6 as an independent prognostic marker in EC and as a potential target for ADCs, particularly in serous and carcinosarcoma subtypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.